More encouraging data from Vertex in cystic fibrosis

Shares in East Coast, USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) jumped more than 5% on Tuesday, after the firm said people treated with its triple combination cystic fibrosis (CF) therapy fared well in two Phase III tests.

Data from the trials examining the experimental VX-659, together with tezacaftor and Kalydeco (ivacaftor), show statistically-significant improvements in lung function.

The prespecified interim analysis reveals a mean absolute improvement in ppFEV1 - a commonly used measure of lung function - of 14% from baseline after four weeks, compared to triple placebo.